Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619 at ASCO 2023

Inside the Revolution In the Treatments of Untreatable Diseases
We are now living a great revolution in the treatment of diseases.

We expect to discover novel treatments capable of defeating cancers’ resistance to therapeutics old and new.

We are following on all the firms that are discovering the unknown about life-threatening diseases, including the genetically derived diseases or else.

Yesterday, May 25, 2023, we studied a firm that might be new for many people. Its name is Cullinan Oncology and it announced encouraging data from its novel product CLN-619.

Cullinan Oncology

This content is for paid subscribers.

Please click here to subscribe or here to log in.